Smaller Sales Staffs Expected With More Targeted Marketing Under FDAAA
Executive Summary
Pharmaceutical company sales staffs will be significantly downsized as a result of the risk evaluation and management strategies imposed under the FDA Amendments Act, former Novartis Senior VP Nancy Lurker predicts
You may also be interested in...
FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule
FDA will use its authority to require risk evaluation and mitigation strategies judiciously, according to Chief Medical Officer and CDER Acting Director Janet Woodcock
Avandia Continues To Take Its Toll; GSK Restructuring Will Cut $1.5 Bil., Jobs
Due in part to plummeting Avandia sales, GlaxoSmithKline will cut $1.5 billion in costs through a restructuring program targeting sales and manufacturing, the firm announced in a third quarter sales and earnings call Oct. 24
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.